Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-02
1999-02-09
Stone, Jacqueline M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424 9321, 4351723, 4352401, 4352402, 43524025, 435948, A61K 4800
Patent
active
058694633
ABSTRACT:
Human fetal neuro-derived cell lines are implanted into host tissues. The methods allow for treatment of a variety of neurological disorders and other diseases. A preferred cell line is SVG.
REFERENCES:
patent: 4707448 (1987-11-01), Major
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5032407 (1991-07-01), Wagner et al.
patent: 5082670 (1992-01-01), Gage et al.
Marshall, Science, 269:1050-1055, 1995.
Miller et al., FASEB J., 9:190-199, 1995.
Calver et al., Trends in Gen., 10(5), 1994, 174-178.
Hodgson, Exp. Opin. Ther. Pat., 5(5), 1995, 458-469.
Freed, "Substantia nigra grafts and Parkinson's disease: from animal experiments to human therapeutics trials," Restor. Neurol. Neurosci. 3:109-134 (1991).
Gage et al., "Intracerebral grafting: a tool for the neurobiologist," Neuron 6:1-12 (1991).
Lendahl, "The use of cell lines in neurobiology," Trends in Neurosci. 13:132-137 (1990).
Lindvall et al., "Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease," Science 247:574-577 (1990).
Lindvall et al., "Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease," Arch. Neurol. 46:615-631 (1989).
Major et al., "Establishment of a line of human fetal glial cells that supports JC virus multiplication," Proc. Nat'l Acad. Sci. USA 82:1257-1262 (1985).
Noel et al., "A method for large-scale high-yield isolation of canine pancreatic Islets of Langerhans," Metabolism 31:184-187 (1982).
Plunkett et al., "Implantation of dispersed cells into primate brain," J. Neurosurg. 70:441-445 (1989).
Rosenberg et al., "Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression," Science 242:1575-1577 (1988).
Sun et al., "Microencapsulated Hepatocytes: an in vitro and in vivo study," Biomat., Art. Cells, Art Org., 15:483-496 (1987).
Taylor et al., "Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys," Prog. Brain. Res. 82:543-559 (1990).
Tornatore et al., "Implantation and survival of a human fetal astrocyte cell line in the basal ganglia of the non-human primate, rhesus monkey," J. of Cellular Biochemistry, Abstract Supp. 17E (Keystone Symposium on Gene Therapy, Apr. 12-18, 1993) New York, NY, p. 227, Abstract SZ 115.
Uchida et al., "Transfection of tyrosine hydroxylase CDNA into C6 cells. The synthesis and release of L-DOPA," 3-Biochem. Genetics 110(11):207 (1989) Abstract No. 110:89851p.
Widner et al., "Biolateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-pheyl-1,2,3,6-tetrahydropyridine (MPTP)," New Eng. J. Med. 327:1556-1563 (1992).
Widner and Brundin, "Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis," Brain Res. Rev. 13:287-324 (1988).
Wolff et al., "Grafting fibroblasts genetically modified to produce L-dopa in a rat model of parkinson's disease," Proc. Nat'l Acad. Sci. USA 86:9011-9014 (1989).
Bankiewicz et al., "The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism," J. Neurosurg. 72:231-244 (1990).
Bjorkland et al., "Reconstruction of the Nigrostriatal dopamine pathway by intracerebral Nigral transplants," Brain Res. 177:555-560 (1979).
Brundin, "Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival," Brain Res., 331:251-259 (1985).
Cattaneo, "Identifying and manipulating neuronal stem cells," Trends in Neurosci. 14:338-340 (1991).
Fisher et al., "Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-Dopa," Neuron 6:371-380 (1991).
Major Eugene O.
Tornatore Carlo S.
Milne Andrew
Stone Jacqueline M.
The United States of America as represented by the Department of
LandOfFree
Use of neuro-glial cell lines for transplantation therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of neuro-glial cell lines for transplantation therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of neuro-glial cell lines for transplantation therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1948509